One of the most popular ingredients in the field of  longevity science globally, nicotinamide mononucleotide (NMN) has officially  been listed as a permissible therapeutic ingredient under Australia’s Therapeutic  Goods Administration (TGA). 

This milestone marks the first time NMN is legally permitted as a permissible  ingredient for use in therapeutic goods in Australia, regulated by the TGA – widely  regarded as one of the most rigorous and conservative therapeutic goods  regulators worldwide. 

Longevity Life Sciences (LLS), an Australian biotechnology company, is currently  the only company permitted to supply manufacturers with NMN – under CellVive  NMN™ – as an ingredient for use in products intended for human consumption  in Australia. 

A global leader in NMN innovation, LLS prompted the need to establish one of the  world’s first regulated frameworks for pharmaceutical-grade NMN – bringing  control to a sector previously impacted by grey-market imports and inconsistent  quality. LLS also partnered with international leader in green1 biotechnology and  pharmaceuticals, SyncoZymes. Based in Shanghai, the green pharmaceutical  giant manufactures LLS’ CellVive NMN™ at its green biotech facility. 

LLS is expanding into Hong Kong and mainland China, bringing Australia’s  regulated, pharmaceutical-grade NMN to some of Asia’s most dynamic wellness  markets. 

NMN is a molecule that helps the body replenish NAD+ levels, which are essential  for energy production and DNA repair. It can be taken as an oral supplement to  support NAD+ production. Hailed as an anti-ageing hero, NMN has become a  sought-after ingredient among consumers globally interested in healthy ageing.  

Rapid global growth in the NMN market 

By 2035, the global NMN market is projected to reach USD 3.9 billion in value,  with Asia–Pacific (APAC) countries such as China, India, Japan and South Korea  playing a major role in this growth – currently holding over 38% of the global NMN  market share.2 

Previously restricted to export-use only, many Australians were accessing  unregulated NMN supplements through overseas and domestic suppliers who  were in breach of Australian regulations. Sally Panton, Co-Founder and CEO of  

1 Green refers to green chemistry, low-impact manufacturing, sustainable packaging, and reduced-waste processes. 2 Beta-NMN Market Growth, Trends & Industry Outlook. (2025). Businessresearchinsights.com.  

https://www.businessresearchinsights.com/market-reports/beta-nicotinamide-mononucleotide-nmn-market-104605

Longevity Life Sciences, said the announcement represents the culmination of  years of collaborative work between scientific, academic and regulatory partners. 

“The TGA’s inclusion of NMN as a permissible ingredient reflects the level of  scientific and regulatory rigour required to advance this category responsibly. It  establishes a credible pathway for access in Australia and reinforces Australian sourced NMN as a trusted benchmark across the region.”  

Lucy Canny, Co-Founder and Chief Operating Officer said, “Our mission has  always been to ensure longevity innovation is driven by science and regulation.  This decision paves the way for NMN to enter the market, both locally and further  afield, transparently and with greater safety mechanisms, giving consumers and  our industry partners confidence in the ingredient’s quality and evidence base.” 

First NMN products to be stocked across Australia’s largest pharmacy chain 

Only through regulated manufacturing can NMN meet pharmaceutical-grade  standards. With NMN now regulated by the TGA, Australians and APAC  consumers purchasing Australian NMN products can be confident in the quality,  purity and reliable absorption to support the body’s natural NAD+ production. 

NMN products will be made available to consumers through Chemist Warehouse,  Australia’s largest retail pharmacy chain by revenue and store footprint, marking  the first large-scale national retail distribution of NMN products in the Australian  market. 

Daniel Kinder, Chemist Warehouse’s head of vitamins said the healthy ageing  category has seen sustained growth within Australia in recent years, indicating  increased consumer interest in preventative health measures.  

“The availability of NMN products through mainstream pharmacy retail supports  broader access to an ingredient that, for Australians, until now, had not been  accessible, affordable or appropriately vetted for quality,” said Daniel. 

“Making NMN products accessible matters because healthy ageing should not  become a premium-only intervention: affordability, trusted quality, and clear  education can help broaden the understanding of NMN and its role as a widely  available ingredient, rather than something limited to niche or elite consumers.” 

LLS’ CellVive NMN™ is designed to set the benchmark for NAD+ restoration in  regulated markets, combining pharmaceutical-grade purity, clinical validation,  and TGA compliance